<DOC>
	<DOCNO>NCT00002788</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Combining chemotherapy radiation therapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase I trial study effectiveness high-dose combination chemotherapy follow total-body irradiation peripheral stem cell transplantation treat patient chronic lymphocytic leukemia .</brief_summary>
	<brief_title>High-Dose Chemotherapy Followed Total-Body Irradiation Peripheral Stem Cell Transplantation Treating Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate engraftment autografting CD34 select peripheral blood stem cell ( PBSC ) patient chronic lymphocytic leukemia ( CLL ) . II . Evaluate efficacy CD34 selection purge CLL PBSC collection . III . Determine effectiveness mobilization chemotherapy cyclophosphamide , etoposide , dexamethasone plus filgrastim ( granulocyte colony-stimulating factor ) mobilize PBSC patient . IV . Describe toxicity disease response condition regimen total body irradiation cyclophosphamide patient . OUTLINE : There 3 phase treatment plan : Cytoreductive chemotherapy give conventional chemotherapy . Patients treat least good partial remission . Patients CD34 select peripheral blood stem cell ( PBSC ) store treatment mobilization chemotherapy follow filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) . Cyclosphosphamide ( CTX ) IV give 1 hour . Etoposide ( VP-16 ) give 1-2 hour day 2 . Dexamethasone give 4 time day day 1-3 . G-CSF give subcutaneously daily begin 2 day chemotherapy continue PBSC collection complete . At least 4 week ensue mobilization chemotherapy proceed transplant . Patients treat TBI day -6 , -5 , -4 CTX day -3 -2 . PBSC infuse day 0 . PROJECTED ACCRUAL : A total 15 patient enter study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnostically proven intermediate , advance , high risk chronic lymphocytic leukemia B cell marrow tumor reduce prior therapy Marrow tumor content great 30 % total nucleated cell Patients age 50 high risk disease eligible Patients age 65 intermediate high risk disease fail least 1 therapy include alkylating agent fludarabine eligible No history transformation aggressive lymphoma ( Richter 's syndrome ) PATIENT CHARACTERISTICS : Age : 17 65 Performance status : Karnofsky 70 % 100 % Life expectancy : Not severely limited illness leukemia Hematopoietic : Absolute neutrophil count great 2,000/mm3 ( growth factor support ) Platelet count great 120,000/mm3 ( unless document active autoimmune thrombocytopenia ) Hemoglobin great 10 g/dL ( unless document active autoimmune anemia ) No coexist myelodysplasia Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine clearance least 50 mL/min Cardiovascular : No cardiac disease would limit ability receive cytoreductive therapy compromise survival Pulmonary : No pulmonary disease would limit ability receive cytoreductive therapy compromise survival Other : No HIV antibody Not pregnant PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior radiation therapy chest abdomen great 2,000 Gy</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
</DOC>